1. PTC Therapeutics' Sephience approved for phenylketonuria by FDA. 2. The treatment expected to be the new standard of care. 3. Initial strategy targets 1,200 prescribers across 104 centers. 4. Peak global sales estimated at $2.2 billion by 2031. 5. PTCT stock rose 12.44% post-news release.
The FDA approval indicates strong commercial potential and future revenue growth, akin to historical cases of similar drug approvals leading to significant stock price increases.
The article discusses a critical FDA approval, essential for future revenue prospects, influencing potential investor confidence.
Successful commercial launch and revenue generation from Sephience will have lasting effects on PTCT's financial health, similar to prior successful drug launches in rare diseases.